认知行为治疗失眠预防老年人新发与复发性重性抑郁:一项随机临床试验
这项评估者盲法、平行分组、单中心随机临床试验纳入291名60岁及以上失眠障碍老年人,比较2个月认知行为治疗失眠(CBT-I,n=156)与睡眠教育疗法(SET,n=135)。CBT-I组新发或复发性重性抑郁19例(12.2%),SET组35例(25.9%),总体获益(HR 0.51,95%CI 0.29-0.88,P=0.02);CBT-I组失眠持续缓解者抑郁风险较SET组未持续缓解者降低(HR 0.17,95%CI 0.04-0.73,P=0.02)。
要点
- CBT-I组新发或复发性重性抑郁19例(12.2%),SET组35例(25.9%),HR 0.51(95%CI 0.29-0.88,P=0.02)。
- CBT-I组失眠持续缓解41例(26.3%),SET组26例(19.3%),P=0.03。
- CBT-I组失眠持续缓解者较SET组未持续缓解者抑郁风险降低(HR 0.17,95%CI 0.04-0.73,P=0.02)。
主要发现
- CBT-I组新发或复发性重性抑郁19例(12.2%),SET组35例(25.9%),HR 0.51(95%CI 0.29-0.88,P=0.02),各亚组结果一致。
- CBT-I组失眠持续缓解41例(26.3%),SET组26例(19.3%),P=0.03。
- CBT-I组失眠持续缓解者较SET组未持续缓解者抑郁风险降低(HR 0.17,95%CI 0.04-0.73,P=0.02)。
- CBT-I组完成治疗140例(89.7%),SET组130例(96.3%),χ2=4.9,P=0.03;CBT-I组完成24个月随访114例(73.1%),SET组117例(86.7%),χ2=8.4,P=0.004。
- 方案修改后CBT-I组92例(59.0%)、SET组86例(63.7%)同意延长随访(χ2=0.7,P=0.41),完成36个月随访分别为81例(51.9%)和77例(57.0%)(χ2=0.8,P=0.39)。
关键数值与推荐
- 主要结局为经访谈和《精神障碍诊断与统计手册(第五版)》标准诊断的新发重性抑郁时间。
- 次要结局为抑郁事件前失眠障碍的持续缓解或随访时长。
临床怎么用
- 作者认为,对老年人失眠问题进行社区层面筛查并广泛提供基于CBT-I的失眠治疗,可 substantially 推进该脆弱老年人群的失眠治疗与抑郁预防公共卫生工作。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Older adults with insomnia have a high risk of incident and recurrent depression. Depression prevention is urgently needed, and such efforts have been neglected for older adults. OBJECTIVE: To examine whether treatment of insomnia disorder with cognitive behavioral therapy for insomnia (CBT-I) compared with an active comparator condition, sleep education therapy (SET), prevents major depressive disorder in older adults. DESIGN, SETTING, AND PARTICIPANTS: This assessor-blinded, parallel-group, single-site randomized clinical trial assessed a community-based sample of 431 people and enrolled 291 adults 60 years or older with insomnia disorder who had no major depression or major health events in past year. Study recruitment was performed from July 1, 2012, to April 30, 2015. The trial protocol was modified to extend follow-up from 24 to 36 months, with follow-up completion in July 2018. Data analysis was performed from March 1, 2019, to March 30, 2020. INTERVENTIONS: Participants were randomized to 2 months of CBT-I (n = 156) or SET (n = 135). MAIN OUTCOMES AND MEASURES: The primary outcome was time to incident major depressive disorder as diagnosed by interview and Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) criteria. Secondary outcome was sustained remission of insomnia disorder before depression event or duration of follow-up. RESULTS: Among 291 randomized participants (mean [SD] age, 70.1 [6.7] years; 168 [57.7%] female; 7 [2.4%] Asian, 32 [11.0%] Black, 3 [1.0%] Pacific Islander, 241 [82.8%] White, 6 [2.1%] multiracial, and 2 [0.7%] unknown), 156 were randomized to CBT-I and 135 to SET. A total of 140 participants (89.7%) completed CBT-I and 130 (96.3%) participants completed SET (χ2 = 4.9, P = .03), with 114 (73.1%) completing 24 months of follow-up in the CBT-I group and 117 (86.7%) in the SET group (χ2 = 8.4, P = .004). After protocol modification, 92 (59.0%) of the CBT-I participants and 86 (63.7%) of the SET participants agreed to extended follow-up (χ2 = 0.7, P = .41), with 81 (51.9%) of the CBT-I participants and 77 (57.0%) of the SET group completing 36 months of follow-up (χ2 = 0.8; P = .39). Incident or recurrent major depression occurred in 19 participants (12.2%) in the CBT-I group and in 35 participants (25.9%) in the SET group, with an overall benefit (hazard ratio, 0.51; 95%, CI 0.29-0.88; P = .02) consistent across subgroups. Remission of insomnia disorder continuously sustained before depression event or during follow-up was more likely in CBT-I participants (41 [26.3%]) compared with the SET participants (26 [19.3%], P = .03). Those in the CBT-I group with sustained remission of insomnia disorder had an 82.6% decreased likelihood of depression (hazard ratio, 0.17; 95%, CI 0.04-0.73; P = .02) compared with those in the SET group without sustained remission of insomnia disorder. CONCLUSIONS AND RELEVANCE: The findings of this randomized clinical trial indicate that treatment of insomnia with CBT-I has an overall benefit in the prevention of incident and recurrent major depression in older adults with insomnia disorder. Community-level screening for insomnia concerns in older adults and wide delivery of CBT-I-based treatment for insomnia could substantially advance public health efforts to treat insomnia and prevent depression in this vulnerable older adult population. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01641263.
引用
- Irwin MR, Carrillo C, Sadeghi N, et al. Prevention of Incident and Recurrent Major Depression in Older Adults With Insomnia: A Randomized Clinical Trial. JAMA Psychiatry. 2022. PMID: 34817561. doi:10.1001/jamapsychiatry.2021.3422
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。